摘要:
The present invention relates to an Aβ(X-38 . . . 43) oligomer having a high molecular weight, or a derivative thereof, a process for preparing the oligomer or derivative, compositions comprising the oligomer or derivative, and uses of the oligomer or derivative such as its use for treating or preventing an amyloidosis (e.g. by active immunization), for diagnosing an amyloidosis, and for providing agents that are capable of binding to the Aβ(X-38 . . . 43) oligomer or derivative. The subject invention also describes agents that are capable of binding to the Aβ(X-38 . . . 43) oligomer or derivative, e.g. antibodies, compositions comprising the agents, and uses of the agents such as their use for treating or preventing an amyloidosis (e.g. by passive immunization) and for diagnosing an amyloidosis.
摘要:
An antibody binding to IL33R characterized in that the heavy chain variable domain comprises a CDR3 region of SEQ ID NO:1, a CDR2 region of SEQ ID NO:2 and a CDR1 region of SEQ ID NO:3 and in that the light chain variable domain comprises a CDR3 region of SEQ ID NO:4, a CDR2 region of SEQ ID NO:5 and a CDR1 region of SEQ ID NO:6 or a chimeric, humanized or T cell epitope depleted antibody variant thereof has advantageous properties for the treatment of inflammatory diseases.
摘要翻译:结合IL33R的抗体,其特征在于重链可变结构域包含SEQ ID NO:1的CDR3区,SEQ ID NO:2的CDR2区和SEQ ID NO:3的CDR1区,并且其中轻链可变区 结构域包含SEQ ID NO:4的CDR3区,SEQ ID NO:5的CDR2区和SEQ ID NO:6的CDR1区或嵌合,人源化或T细胞表位缺失的抗体变体具有治疗的有利性质 的炎性疾病。
摘要:
An antibody binding to IL33R characterized in that the heavy chain variable domain comprises a CDR3 region of SEQ ID NO:1, a CDR2 region of SEQ ID NO:2 and a CDR1 region of SEQ ID NO:3 and in that the light chain variable domain comprises a CDR3 region of SEQ ID NO:4, a CDR2 region of SEQ ID NO:5 and a CDR1 region of SEQ ID NO:6 or a chimeric, humanized or T cell epitope depleted antibody variant thereof has advantageous properties for the treatment of inflammatory diseases.
摘要翻译:结合IL33R的抗体,其特征在于重链可变结构域包含SEQ ID NO:1的CDR3区,SEQ ID NO:2的CDR2区和SEQ ID NO:3的CDR1区,并且其中轻链可变区 结构域包含SEQ ID NO:4的CDR3区,SEQ ID NO:5的CDR2区和SEQ ID NO:6的CDR1区或嵌合,人源化或T细胞表位缺失的抗体变体具有治疗的有利性质 的炎性疾病。